KSQ Therapeutics

A clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics discovery platform.

The USA-based company's CRISPRomics discovery engine enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas. In particular, KSQ is advancing a pipeline of tumor- and immune-focused drug candidates to treat cancer.

Latest KSQ Therapeutics News & Features

KSQ Therapeutics bags deal with Roche for clinical-stage USP1 Inhibitor

14 July 2023

Deal-hungry Ono acquires KSQ programs in oncology

25 January 2023

KSQ collaborates with Takeda in I-O

13 January 2021

BRIEF—KSQ Therapeutics secures $80 million in series C round

1 October 2018

KSQ Therapeutics

Latest KSQ Therapeutics News & Features

Today's issue